newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

  • Eikon Therapeutics announced the acceptance of seven abstracts for presentation at the 2026 ESMO Congress in Madrid, Spain.
  • Updates on EIK1001, a TLR7/8 dual agonist, will include data from the TeLuRide-005 Phase 2 trial in stage IV NSCLC patients receiving the drug with pembrolizumab and chemotherapy.
  • Initial data will be presented for EIK1003, a non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy for advanced solid tumors.
  • Initial results will be shared regarding EIK1003 combined with abiraterone for metastatic prostate cancer.
  • Data from a Phase 1/2 study of EIK1004, a CNS-penetrant PARP1 inhibitor, in advanced solid malignancies will be discussed.
  • Initial safety, tolerability, and pharmacokinetics data will be provided for EIK1005, a Werner helicase inhibitor.
  • Roy Baynes, M.D., Ph.D., Chief Medical Officer, stated the presentations highlight pipeline progress and evidence supporting the differentiation of lead programs.
  • The company is a late-stage clinical biopharmaceutical firm focused on oncology therapies developed via its proprietary single molecule tracking system.
  • Forward-looking statements in the release carry risks related to funding, development timelines, and potential product failures.